Zobrazeno 1 - 10
of 66
pro vyhledávání: ''
Autor:
Ursa Brown-Glaberman, Hannah M. Linden, Lynn Symonds, Jennifer M. Specht, Eve T. Rodler, Isaac C. Jenkins, Xiaoyu Chai, Georgiana K. Ellis, Pavani Chalasani, Jinny Riedel, Brenda F. Kurland, Julie Gralow, Alison Stopeck, Qian Wu, Vijayakrishna V K Gadi
Publikováno v:
Clin Breast Cancer
INTRODUCTION Neoadjuvant chemotherapy is standard treatment for locally advanced (LABC) or inflammatory breast cancer (IBC). We hypothesized adding sunitinib, a tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity, to an anthracycli
Autor:
Margaret M. Kozak, Frederick M. Dirbas, Emily Walck, Rie von Eyben, Clare E. Jacobson, Kathleen C. Horst, Paulina M. Gutkin
Publikováno v:
Clinical Breast Cancer. 20:431-438
Background Optimal surgical management of limited axillary nodal disease following neoadjuvant chemotherapy (NAC) for breast cancer is evolving. Concerns exist with respect to leaving residual disease in the axilla when omitting axillary lymph node d
Publikováno v:
Clinical Breast Cancer. 20:e82-e88
Background Clinical response evaluation by image examination after neoadjuvant chemotherapy for breast cancer is important for determining drug response and progression. Mammography is less correlated with pathologic response assessment than magnetic
Autor:
Ritu Aneja, Zhimin Wei, Jane L. Meisel, Xiaoxian Li, Rita Nahta, Aili Suo, Chao Zhang, Ruth O'Regan, Jing Zhao, Caitlin E. Taylor, Zaibo Li, Uma Krishnamurti
Publikováno v:
Clinical Breast Cancer. 20:19-24
Background HER2-targeted neoadjuvant therapy has high efficacy in treating HER2-positive breast cancer. Response to neoadjuvant therapy helps clinicians make treatment decisions and make estimates about prognosis. This study examined clinicopathologi
Autor:
Tomohiro Ochi, Seigo Nakamura, Naoki Hayashi, Koyu Suzuki, Hideko Yamauchi, Maki Namura, Hiroko Tsunoda
Publikováno v:
Clinical Breast Cancer. 19:71-77
Background Magnetic resonance imaging (MRI) or ultrasonography (US) alone is limited in the ability to predict the pathologic complete response (pCR) accurately after neoadjuvant chemotherapy (NAC). The aim of the present study was to predict the pCR
Autor:
John D. Hainsworth, John D. Zubkus, Mythili Shastry, Patrick J. Ward, L Finney, Denise A. Yardley, Aruna Mani, Dianna Shipley, Gail Lynn Shaw Wright, Laura M. DeBusk
Publikováno v:
Clinical Breast Cancer. 19:1-9
Background Eribulin mesylate is a non–taxane microtubule inhibitor effective in the treatment of metastatic breast cancer refractory to anthracyclines and taxanes. In preclinical studies, additional mechanisms of eribulin included reversal of epith
Autor:
Hiroaki Toba, Kazumasa Okumura, Akira Tangoku, Naoki Hino, Mayumi Ikeuchi, Takahiro Yoshida, Hirokazu Takechi, Masami Morimoto, Aya Nishisho, Misako Nakagawa
Publikováno v:
Clinical Breast Cancer. 19:10-16
Background To improve the pathological complete response (pCR) rate, we devised new neoadjuvant chemotherapy. Efficacy and safety of the oral fluoropyrimidine derivative S-1 (Taiho Pharmaceutical Co, Tokyo, Japan) combined with low-dose docetaxel (S-
Autor:
Zhe Wang, Guangdong Hou, Juliang Zhang, Rui Ling, Ying Wu, Jingjing Xiao, Niuniu Hou, Lili Guo
Publikováno v:
Clinical breast cancer. 20(6)
To explore the independent predictors of pathologic complete remission response (pCR) for Chinese patients with breast cancer (BC) after preoperative chemotherapy and to develop an individualized nomogram for predicting the probability of pCR.The cli
Autor:
Y Liu, Raymond C. Bergan, Yueping Liu, Xiangmei Zhang, Zhenzhen Zhang, Motomi (Tomi) Mori, Miao Cao, Shiuh Wen Luoh, Beichen Liu
Publikováno v:
Clinical breast cancer. 20(4)
Background To explore the potential advantage of preoperative anti-angiogenosis therapy, we implemented a study to evaluate the efficacy of recombinant human endostatin (EN) in combination with neoadjuvant chemotherapy in the treatment of stage III b
Autor:
Junko Takei, Naoki Hayashi, Koyu Suzuki, Emiko Morishita, Maki Namura, Atsushi Yoshida, Hiroko Tsunoda, Hideko Yamauchi, Hiroshi Yagata
Publikováno v:
Clinical Breast Cancer. 18:128-134
Introduction The influence of breast cancer (BC) subtype in discrepancies between pathologic complete response (pCR) and complete response by magnetic resonance imaging (MRI-CR) after neoadjuvant chemotherapy (NAC) have not been discussed well. We ev